Citigroup Maintains Buy Rating for Arcus Biosciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Citigroup has maintained its Buy rating for Arcus Biosciences (NYSE:RCUS) and increased its price target from $40.00 to $41.00. Shares of Arcus Biosciences are trading up 24.06% over the last 24 hours, at $21.71 per share.
May 26, 2023 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup maintains Buy rating for Arcus Biosciences and raises price target to $41.00. Shares are up 24.06% in the last 24 hours.
Citigroup's maintained Buy rating and increased price target for Arcus Biosciences indicate a positive outlook for the stock. The recent 24.06% increase in share price also supports this positive sentiment. As a result, the stock is likely to experience upward momentum in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100